Klaus Eistetter

This inventor holds 16 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Byk Gulden Lomberg Chemische Fabrik Gmbh, Byk Gulden Lomberg Chemische Fabrik Gesellschaft MIT Beschrankter Haftung, Altana Pharma Ag. Active years: 1980-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klaus Eistetter. Retrieved from https://idiyas.com/inventor/klaus-eistetter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 7)

% Patents Active = 81.3

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 2.1

ph-index = 7

Forward Citations = 173(Granted Patents)

Location History:

Konstanz, DE (1984)
Constance, DE (1980 - 2017)

Company Filing History:

8 out of 136

Byk Gulden Lomberg Chemische Fabrik Gmbh

patents

3 out of 6

Byk Gulden Lomberg Chemische Fabrik Gesellschaft MIT Beschrankter Haftung

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Years Active: 1980-2017

Loading Chart...

Areas of Expertise:

PDE 4 Inhibitors

Pulmonary Surfactants

Oxirancarboxylic Acids

Analgesics

Dosage Forms

Compositions

Medicaments

Synthesis

Benzylpyrrolidines

Phenoxyalkyl Compounds

Therapeutics

Dosing Devices

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9713682 - Device for dosing and dry nebulization (2017-07-25),

2. 9468598 - Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient (2016-10-18),

3. 8431154 - Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient (2013-04-30),

4. 7951397 - Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient (2011-05-31),

5. 6998410 - Compositions (2006-02-14),

6. 6436970 - Compositions for the treatment of ARDS or IRDS containing 3-(cycloproplymethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamide and lung surfactant (2002-08-20),

7. 6315983 - Process for the production of powdered pulmonary surfactant preparations (2001-11-13),

8. 4946866 - Use of oxirancarboxylic acids for the treatment of hyperlipemia (1990-08-07),

9. 4430339 - Substituted oxiranecarboxylic acids, their preparation and their use as (1984-02-07),

10. 4395414 - Substituted quinolinone-alkanecarboxylic acids and medicaments (1983-07-26),

11. 4337267 - Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids, (1982-06-29),

12. 4333942 - Anti-depressant and analgesic 4-phenoxypiperidines (1982-06-08),

13. 4324796 - Substituted oxiranecarboxylic acids, their use and medicaments (1982-04-13),

14. 4279918 - 2-(Nuclearly-substituted)benzylpyrrolidines (1981-07-21),

15. 4221788 - 2-(Optionally-substituted)benzylperhydroazepines for analgesia and (1980-09-09),

Title: Innovations of Klaus Eistetter: Advancements in Drug Delivery Systems

Introduction

Klaus Eistetter, an accomplished inventor based in Constance, Germany, has made significant contributions to the field of drug delivery technology. With a remarkable portfolio of 16 patents, his work primarily focuses on innovations that enhance the efficiency of nebulization devices and oral dosage formulations.

Latest Patents

Among his notable inventions is a device for dosing and dry nebulization, which addresses the administration of nebulizable materials, including anti-infective agents and immunomodulators. This device features a nebulization channel equipped with two attachment pieces and a source of compressed carrier gas, facilitating precise gas pressure pulses for effective nebulization. The innovative design includes a reservoir, gas-tight with respect to the environment, that allows for pressure compensation and enhances the delivery mechanism.

Another recent patent describes an oral dosage form that incorporates a PDE 4 inhibitor as its active ingredient, utilizing polyvinylpyrrolidon (PVP) as an excipient. This formulation is tailored for oral administration, and is particularly significant given the low solubility of the active ingredient.

Career Highlights

Eistetter's career reflects a consistent dedication to innovation within the pharmaceutical industry. He has been associated with several reputable companies, notably Byk Gulden Lomberg Chemische Fabrik GmbH and Byk Gulden Lomberg Chemische Fabrik Gesellschaft mit Beschränkter Haftung. His work at these establishments has undoubtedly contributed to advancing drug delivery systems and improving patient outcomes.

Collaborations

Throughout his career, Klaus Eistetter has collaborated with several esteemed professionals, including Erich Rapp and Rango Dietrich. These partnerships have facilitated a rich exchange of ideas and expertise, further enhancing the quality and applicability of his inventions.

Conclusion

Klaus Eistetter's innovative spirit and commitment to improving drug delivery methods mark him as a significant figure in the realm of pharmaceutical technologies. His several patents reflect a profound impact on the industry, promising advancements that could lead to enhanced therapeutic efficacy and improved patient care.

Profile summary based on public USPTO records.